|
ZFP36L2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6242562850266E-12 |
| Normal-vs-Stage2 |
<1E-12 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
4.338600E-01 |
| Stage1-vs-Stage3 |
1.874360E-01 |
| Stage1-vs-Stage4 |
2.34919999999583E-05 |
| Stage2-vs-Stage3 |
8.546000E-01 |
| Stage2-vs-Stage4 |
3.567900E-02 |
| Stage3-vs-Stage4 |
1.841740E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.17900031351803E-10 |
| Normal-vs-Asian |
1.62470037423645E-12 |
| Caucasian-vs-AfricanAmerican |
6.657800E-01 |
| Caucasian-vs-Asian |
9.021000E-01 |
| AfricanAmerican-vs-Asian |
7.468200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.550600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.37380000042597E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.713200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.461400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.619200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.888400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.257200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.421800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.00670000405756E-08 |
| Classical-VS-Follicular |
4.877400E-01 |
| Classical-VS-Other |
4.745400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.45009999999546E-05 |
| Tall-VS-Other |
9.561800E-02 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
4.630800E-01 |
| Follicular-VS-Normal |
1.62447832963153E-12 |
| Other-VS-Normal |
1.430330E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.304600E-01 |
|
|
